Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

1.

Receptor tyrosine kinase alterations and therapeutic opportunities in squamous cell carcinoma of the lung.

Wang D, Du L, Liu Q, Liu X, Wang Z.

Cancer Chemother Pharmacol. 2013 Oct;72(4):725-31. Review.

PMID:
23959461
[PubMed - indexed for MEDLINE]
2.

Genetic insight and therapeutic targets in squamous-cell lung cancer.

Sos ML, Thomas RK.

Oncogene. 2012 Nov 15;31(46):4811-4. doi: 10.1038/onc.2011.640. Epub 2012 Jan 23. Review.

PMID:
22266863
[PubMed - indexed for MEDLINE]
3.

Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far?

Fischer B, Marinov M, Arcaro A.

Cancer Treat Rev. 2007 Jun;33(4):391-406. Epub 2007 Mar 26. Review.

PMID:
17368733
[PubMed - indexed for MEDLINE]
4.

Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities.

Perez-Moreno P, Brambilla E, Thomas R, Soria JC.

Clin Cancer Res. 2012 May 1;18(9):2443-51. doi: 10.1158/1078-0432.CCR-11-2370. Epub 2012 Mar 8. Review.

PMID:
22407829
[PubMed - indexed for MEDLINE]
Free Article
5.

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, Brace LE, Woods BA, Lin W, Zhang J, Deng X, Lim SM, Heynck S, Peifer M, Simard JR, Lawrence MS, Onofrio RC, Salvesen HB, Seidel D, Zander T, Heuckmann JM, Soltermann A, Moch H, Koker M, Leenders F, Gabler F, Querings S, Ansén S, Brambilla E, Brambilla C, Lorimier P, Brustugun OT, Helland A, Petersen I, Clement JH, Groen H, Timens W, Sietsma H, Stoelben E, Wolf J, Beer DG, Tsao MS, Hanna M, Hatton C, Eck MJ, Janne PA, Johnson BE, Winckler W, Greulich H, Bass AJ, Cho J, Rauh D, Gray NS, Wong KK, Haura EB, Thomas RK, Meyerson M.

Cancer Discov. 2011 Jun;1(1):78-89. doi: 10.1158/2159-8274.CD-11-0005.

PMID:
22328973
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.

Uribe P, Gonzalez S.

Pathol Res Pract. 2011 Jun 15;207(6):337-42. doi: 10.1016/j.prp.2011.03.002. Epub 2011 Apr 29. Review.

PMID:
21531084
[PubMed - indexed for MEDLINE]
7.

[Recent changes in the therapeutic strategy for NSCLC in association with new anti-cancer agents].

Yatabe Y.

Rinsho Byori. 2013 Apr;61(4):328-33. Review. Japanese.

PMID:
23855189
[PubMed - indexed for MEDLINE]
8.

Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer.

Niederst MJ, Engelman JA.

Sci Signal. 2013 Sep 24;6(294):re6. doi: 10.1126/scisignal.2004652. Review.

PMID:
24065147
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls.

Tolmachev V, Stone-Elander S, Orlova A.

Lancet Oncol. 2010 Oct;11(10):992-1000. doi: 10.1016/S1470-2045(10)70088-7. Epub 2010 Jul 26. Review.

PMID:
20667780
[PubMed - indexed for MEDLINE]
10.

Epidermal growth factor receptor family in lung cancer and premalignancy.

Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA Jr.

Semin Oncol. 2002 Feb;29(1 Suppl 4):3-14. Review.

PMID:
11894009
[PubMed - indexed for MEDLINE]
11.

Therapeutic targeting of receptor tyrosine kinases in lung cancer.

Choong NW, Ma PC, Salgia R.

Expert Opin Ther Targets. 2005 Jun;9(3):533-59. Review.

PMID:
15948672
[PubMed - indexed for MEDLINE]
12.

A new target for therapy in squamous cell carcinoma of the lung.

Ohashi K, Pao W.

Cancer Discov. 2011 Jun;1(1):23-4. doi: 10.1158/2159-8274.CD-11-0069. Epub 2011 Apr 14.

PMID:
22586316
[PubMed - indexed for MEDLINE]
13.

ALK inhibitor.

Sakamoto H.

Nihon Yakurigaku Zasshi. 2013 Jul;142(1):48-50. Review. No abstract available.

PMID:
23842228
[PubMed - indexed for MEDLINE]
14.

Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.

Rodig SJ, Shapiro GI.

Curr Opin Investig Drugs. 2010 Dec;11(12):1477-90. Review.

PMID:
21154129
[PubMed - indexed for MEDLINE]
15.

Receptor tyrosine kinases and targeted cancer therapeutics.

Takeuchi K, Ito F.

Biol Pharm Bull. 2011;34(12):1774-80. Review.

PMID:
22130229
[PubMed - indexed for MEDLINE]
Free Article
16.

Recent advances of novel targeted therapy in non-small cell lung cancer.

Katzel JA, Fanucchi MP, Li Z.

J Hematol Oncol. 2009 Jan 21;2:2. doi: 10.1186/1756-8722-2-2. Review.

PMID:
19159467
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.

Pillay V, Allaf L, Wilding AL, Donoghue JF, Court NW, Greenall SA, Scott AM, Johns TG.

Neoplasia. 2009 May;11(5):448-58, 2 p following 458.

PMID:
19412429
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy.

Abounader R.

Expert Rev Anticancer Ther. 2009 Feb;9(2):235-45. doi: 10.1586/14737140.9.2.235. Review.

PMID:
19192961
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

[New biological treatments for lung cancer].

Zalcman G, Richard N, Bergot E.

Rev Pneumol Clin. 2007 Feb;63(1):20-8. Review. French.

PMID:
17457280
[PubMed - indexed for MEDLINE]
20.

Phosphoproteomics of collagen receptor networks reveals SHP-2 phosphorylation downstream of wild-type DDR2 and its lung cancer mutants.

Iwai LK, Payne LS, Luczynski MT, Chang F, Xu H, Clinton RW, Paul A, Esposito EA, Gridley S, Leitinger B, Naegle KM, Huang PH.

Biochem J. 2013 Sep 15;454(3):501-13. doi: 10.1042/BJ20121750.

PMID:
23822953
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk